RU2007125208A - Способ снижения биологического возраста (омоложения организма)
- Google Patents
Способ снижения биологического возраста (омоложения организма)
Download PDF
Info
Publication number
RU2007125208A
RU2007125208ARU2007125208/14ARU2007125208ARU2007125208ARU 2007125208 ARU2007125208 ARU 2007125208ARU 2007125208/14 ARU2007125208/14 ARU 2007125208/14ARU 2007125208 ARU2007125208 ARU 2007125208ARU 2007125208 ARU2007125208 ARU 2007125208A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Виталий Иванович Донцов (RU), Виталий Иванович Донцов, В чеслав Николаевич Крутько (RU), Вячеслав Николаевич Крутько, Алексей Ярославович Чижов (RU), Алексей Ярославович ЧижовfiledCriticalВиталий Иванович Донцов (RU)
Priority to RU2007125208/14ApriorityCriticalpatent/RU2404784C2/ru
Publication of RU2007125208ApublicationCriticalpatent/RU2007125208A/ru
Application grantedgrantedCritical
Publication of RU2404784C2publicationCriticalpatent/RU2404784C2/ru
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Claims (1)
Способ снижения биологического возраста (омоложения организма), отличающийся тем, что для обращения возрастных изменений используется препарат «Трансфер-фактор» в дозе 1-3 капсулы в день в расчете на массу 60-80 кг.
RU2007125208/14A2007-07-042007-07-04Способ снижения биологического возраста (омоложения организма)
RU2404784C2
(ru)
odt; composição de odt; método para a preparação de um tablete de odt multiparticulado, método para tratar ou prevenir náusea e vômito pós operatória ou náusea e vômito pós- alta por até 24 horas após a dosagem, método para tratar pu prevenir náusea por até 24 horas após a dosagem e método para tratar ou prevenir náusea e vômito associados a radioterapia em pacientes que recebem ou irradiação de corpo total, dose alta única ao abdômen, ou frações diárias ao abdômen por até 24 horas após a dosagem
Potential of melatonin for the treatment or prevention of obesity: an urgent need to include weight reduction as a secondary outcome in clinical trials of melatonin in obese patients with sleep disorders
Chemical compounds derived from Yi traditional medicine, Yunnan bat study, & brown algae for use in therapy or prophylaxis for the medical condition COVID-19